Company Overview of Fabrus, LLC
Fabrus, LLC, a biotechnology company, engages in discovering, developing, and engineering therapeutic antibodies. Its antibodies hit in various stages of development against the cancer targets DLL4, ErbB1 (EGFR), ErbB2 (Her2), ErbB3, P-Cadherin, c-Ron, c-Met, Axl, and several undisclosed targets. The company also offers cell-based discoveries that allow direct screening for antibody leads on intact cells; technologies to achieve affinity maturation, internalization, and pH dependent binding optimization for recombinant antibodies; and technologies to use flow cytometry to achieve multiplexed discovery directly on living cells. Fabrus, LLC was founded in 2007 and is based in La Jolla, Califor...
11099 North Torrey Pines Road
La Jolla, CA 92037
Founded in 2007
Key Executives for Fabrus, LLC
Compensation as of Fiscal Year 2015.
Fabrus, LLC Key Developments
Fabrus, LLC Auditor Raises 'Going Concern' Doubt
Jul 25 14
Fabrus, LLC filed its Annual on Jul 25, 2014 for the period ending Dec 31, 2013. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Senesco Technologies Inc. and Fabrus Announces New Members to its Board of Combined Company
May 19 14
The Board of Directors of the combined company of Senesco Technologies Inc. and Fabrus Inc. is chaired by Dr. Harlan Waksal, founder of ImClone Systems and also includes: Dr. Philip Frost, Chairman and CEO of Opko Health Inc. and the Chairman of Teva Pharmaceuticals; Mr. Christopher Forbes, Vice Chair, Forbes Media, LLC; Mr. David Rector, Principal, David Stephen Group; Mr. John N. Braca; Former, Venture and Operational Investor, SR One and EuclidSR Partners; Dr. Vaughn V. Smider, Chief Scientific Officer and acting CEO, Senesco; Mr. Steven D. Rubin, Executive Vice President at OPKO Health Inc. The officers of the combined company are: Dr. Vaughn V. Smider, Chief Scientific Officer and acting CEO; Dr. Leslie J. Browne, President; Joel Brooks, Chief Financial Officer, Treasurer and Secretary; Dr. James Graziano, Chief Technology Officer; Dr. Miguel de los Rios, Vice President, Research; Professor John E. Thompson, Scientific Founder; Richard Dondero, Vice President, Preclinical Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|